GlassScriptPhysician profile
Shelby Morrisroe
NPI 1164666228
$10,632.85
in general payments reported to CMS, 2019-2025
58 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 78% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $943 · 2020: $557 · 2021: $926 · 2022: $2,423 · 2023: $2,627 · 2024: $1,297 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Travel and Lodging: $888 · Honoraria: $350 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.52 |
| Travel and Lodging | $887.50 |
| Honoraria | $350.00 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $1,588.42 | 2022-2023 | |
| Abbvie INC. | $1,204.41 | 2019-2025 | |
| Astellas Pharma US INC | $1,121.93 | 2019-2025 | Myrbetriq, Veozah |
| Axonics, INC. | $1,070.19 | 2020-2024 | Axonics, Bulkamid |
| Teleflex LLC | $573.70 | 2022-2025 | Barrigel, Urolift, Solesta |
| Medtronic, INC. | $530.93 | 2021-2025 | Interstim, Altaviva |
| Biotissue Holdings INC. | $444.69 | 2021-2024 | |
| Janssen Biotech, INC. | $338.61 | 2019-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $337.89 | 2020-2025 | Provenge |
| Sumitomo Pharma America, INC. | $336.97 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $255.06 | 2019-2025 | |
| Pfizer INC. | $199.96 | 2019-2025 | |
| Allergan, INC. | $177.00 | 2019-2021 | |
| Boston Scientific Corporation | $172.95 | 2019-2025 | Solyx Sis System, Axonics |
| Progenics Pharmaceuticals, INC. | $157.80 | 2021-2025 | Pylarify |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,039,146.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelby Morrisroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.